Pharmafile Logo
Pharmafocus logo
Advanced Search

olaparib

Showing 10 posts of 10 posts found.

nice_new_london_office_internal_2_8

NICE fail to recommend AstraZeneca’s cancer drug Olaparib on cost effectiveness basis

November 9, 2018
Medical Communications, Sales and Marketing AstraZeneca, NHS, NICE, UK, olaparib, pharma

Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib …

News
Lynparza

AZ’s Lynparza gets prostate cancer breakthrough status

January 28, 2016
Sales and Marketing AstraZeneca, Breakthrough Therapy Designation, FDA, lynparza, olaparib, prostate cancer

AstraZeneca’s Lynparza has been granted breakthrough therapy designation by the FDA as a monotherapy for the treatment of a specific …

News
Lynparza

NICE recommends AstraZeneca’s Lynparza after price reduction

December 11, 2015
Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer

NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …

News

NICE Lynparza rejection labelled ‘hard to understand’

June 2, 2015
Sales and Marketing AstraZeneca, NICE, lynparza, olaparib

AstraZeneca has appealed to the government to put ‘urgent transitional measures’ in place to make sure patients can access innovative …

News
AZ image

AstraZeneca drops CDF application

January 12, 2015
Sales and Marketing AstraZeneca, CDF, Cancer, NHS, NICE, lynparza, olaparib

AstraZeneca has withdrawn its application for its drug Lynparza to be on the Cancer Drugs Fund (CDF), citing concerns with …

News
Astrazeneca image

AstraZeneca ovarian cancer drug approved in Europe

December 18, 2014
Sales and Marketing AstraZeneca, BRCA, Cambridge, Cancer, FDA, lynparza, olaparib, ovarian

The European Commission has approved AstraZeneca’s Lynparza for the treatment of advanced BRCA-mutated ovarian cancer. Lynparza (olaparib) has been approved …

News
AZ image

AZ oncology drug a ‘Phoenix from the flames’

October 27, 2014
Sales and Marketing AstraZeneca, CHMP, EC, lynparza, olaparib, oncology

As the possibility of a deal with Pfizer fades, AstraZeneca is continuing its argument for independence as a key cancer …

News
astrazeneca image

FDA rejects olaparib

June 27, 2014
Sales and Marketing AstraZeneca, Cancer, FDA, PARP, adp, olaparib

AstraZeneca has been dealt a blow by a key advisory committee to the US Food and Drug Administration, which has …

News
Astrazeneca image

AstraZeneca faces olaparib questions

June 24, 2014
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, FDA, olaparib, ovarian

AstraZeneca is facing questions from US regulators over the efficacy of one of its most promising late-stage treatments. Olaparib is …

News
astrazeneca image

AstraZeneca begins olaparib programme

September 4, 2013
Sales and Marketing AstraZeneca, olaparib, ovarian cancer

AstraZeneca has begun recruitment in its Phase III programme for olaparib, a potential first-in-class oral poly ADP ribose polymerase (PARP) …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024